Two-dose vs three-dose hepatitis B vaccine for cirrhosis
Part of Digestive system, Infections clinical trials.
This study compares giving the hepatitis B vaccine in 2 doses versus 3 doses for people with cirrhosis who do not yet have protection against hepatitis B. It may help your care team choose the schedule most likely to build lasting immunity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have cirrhosis and be seen at Mercy Medical Center’s hepatology clinic between 09/2020 and 07/2021
- Have no hepatitis B protection (anti-HBs blood test result under 10 mIU/mL)
- Have never been exposed to hepatitis B before
- Do not have a history of a serious allergic reaction to a hepatitis B vaccine, its ingredients, or yeast
- Not be a post–liver transplant patient
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This Phase 3 study checks whether an undiluted IV infusion of I.V.-Hepabig inj is safe and works to help prevent hepatitis B from coming back after a liver transplant. It is mainly for adults who had a hepatitis B–related liver transplant and already received Hepabig regularly.
This study tests two daily doses of the medicine entecavir to see which one better controls the hepatitis B virus in people with advanced liver scarring (cirrhosis). It aims to find the most effective dose to improve liver health.
This Phase 1 study tests a stem cell product to see if it is safe and how it affects people with worsening hepatitis B-related cirrhosis. It may help researchers understand whether the treatment could improve liver function in this stage of illness.
This study checks whether a single dose of the hepatitis A vaccine helps protect people with cirrhosis who have no immunity. It aims to see how well the vaccine works and your body's response.
This trial tests a new vaccine to treat chronic hepatitis B. It's for people who have been on antiviral medication for at least 6 months and still have a low level of the virus in their blood.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.